Avertto is the first insertable medical device with an AI alert of impending strokes.
Stroke is a $1T problem; it is the leading cause of disability. Stroke is treatable if detected in time; however, 85% remain untreated.
Avertto is a unique, patented, subcutaneous telemonitoring medical device that uses AI and signal analysis to detect changes in the carotid pulse waves, send timely alerts to prevent stroke before neurological damage occurs to healthcare providers, and enable early treatment. Avertto's hybrid go-to-market strategy of in-patient clinical studies with a rigorous insertable domesticated regulatory pathway is the catalyst for large-scale adoption in the home market. The final home market addresses 120M patients yearly with stroke risk (TAM $500K). We are seasoned, diverse entrepreneurs who raised $2M. Avertto has proof of concept, running blinded clinical studies to prove value in 7 clinical sites (Israel, Spain, and the USA). Avertto will change the standard of care and make lives worth living longer.
Company Details
- Employees
- 12
- Founded
- -
- Address
- House 1037, Aderet,n/a 9985000,israel
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- https://Avertto.com/
- Keywords
- INNOVENTRIC.
- HQ
- Aderet, N/A
Avertto Questions
Avertto's website is https://Avertto.com/
Avertto's LinkedIn profile is https://il.linkedin.com/company/avertto
Avertto has
12 employees.
View email and phone details for 12
employees at Avertto.
Avertto's industry is
Hospitals and Health Care
Avertto's top competitors are
Aivf,
Aisap,
Anicca Health,
Epilog,
Aneuscreen,
Innoventric,
Innereye,
Algosensus,
Adam Cogtec,
Curesponse.
Avertto's categories are Hospitals and Health Care
Avertto's founding year is 2019
